Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
J Gastrointestin Liver Dis ; 30(3): 404-406, 2021 09 21.
Article in English | MEDLINE | ID: mdl-34551028

ABSTRACT

Various endoscopic techniques have been described for the treatment of post-operative colonic strictures. Our aim is to report a solely EUS-guided recanalization procedure for a complete rectal stricture, without the use of fluoroscopy or stenting. A 66-year-old male was submitted to low anterior resection and protective ileostomy for rectal adenocarcinoma, complicated with complete anastomotic stricture 6 months later. The patient was treated with a modified EUS-guided rendezvous technique. A colonoscope was advanced through the ileostomy to the sigmoid colon, which was subsequently filled with water. A linear echoendoscope was advanced transanally to the distal part of the rectal anastomosis. The proximal colon was punctured with a 19G needle and a guidewire was advanced through the needle. The rectocolonic fistula tract was first dilated by graduated dilation catheters. Subsequently, progressive pneumatic dilatation was performed. There were no post-procedural complications. At 6-month follow-up the anastomosis was patent, with no significant stricture recurrence. In conclusion, a rendezvous technique for EUS-guided recanalization of complete rectal anastomotic strictures is feasible and safe in a non-radiology assisted setting. In selected cases of distal stenoses balloon dilation could effectively serve as the sole treatment, without the adjunct of stent placement.


Subject(s)
Anastomosis, Surgical , Endoscopy , Rectum , Ultrasonography , Aged , Anastomosis, Surgical/adverse effects , Constriction, Pathologic , Endoscopy/methods , Fluoroscopy , Humans , Male , Rectum/diagnostic imaging , Rectum/surgery , Stents , Ultrasonography/methods
2.
BMC Endocr Disord ; 16: 8, 2016 Feb 12.
Article in English | MEDLINE | ID: mdl-26872616

ABSTRACT

BACKGROUND: The rare incidence of neuroendocrine neoplasms (NENs) has contributed to a paucity of large epidemiologic studies of patients with this condition. We investigated the occurrence and clinicopathologic features of NENs in Greece. METHODS: Between October 2010 and November 2012 we collected data on 246 newly diagnosed patients from a broad-based multi-institutional registry that comprises eight academic and hospital sites in Greece. The WHO 2010 pathologic classification and the 7th AJCC Staging system was applied in all cases. RESULTS: Of all patients 94 % had a sporadic and 6 % a multiple endocrine neoplasia tumor; 63.4 % were gastroenteropancreatic-(GEP)-NENs, 17.9 % Head & Neck NENs, 9.8 % NENs of Unknown Primary, 6.5 % Lung NENs and 2.4 % Pheochromocytomas. Gastric and pancreatic NENs were the most common primary sites. Poorly differentiated neuroendocrine carcinomas (NEC) were 9.3 %, all sporadic. Fifteen percent of patients were asymptomatic at presentation, 24 % had a first symptom of the disease related to endocrine syndrome and 61 % had symptoms related to locally advanced or metastatic disease. Metastatic disease was established in 25 % of tumors most frequently in the GEP NEN group. Findings are presented according to Ki-67 distribution. MRI had a higher diagnostic positive yield than Octreoscan. Somatostatin analogs, lanreotide and octreotide acetate, were prescribed at 38.5 & 61.5 % of NEN patients respectively and were found to be equally effective at providing symptomatic relief. CONCLUSIONS: This is to our knowledge the first study of a Greek tumor registry and one of the few European Registries providing information regarding clinicopathologic characteristics and therapies in patients with neuroendocrine tumors of various origin sites, beyond GEP NENs.


Subject(s)
Neuroendocrine Tumors/epidemiology , Registries/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , Female , Gastrointestinal Neoplasms/epidemiology , Gastrointestinal Neoplasms/pathology , Greece/epidemiology , Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/pathology , Humans , Incidence , Male , Middle Aged , Neuroendocrine Tumors/pathology , Pancreatic Neoplasms/epidemiology , Pancreatic Neoplasms/pathology , Prospective Studies , Young Adult
3.
J Med Virol ; 84(8): 1217-23, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22711349

ABSTRACT

Hepatitis C virus genotype 4 (HCV-4) is spreading beyond Africa and the Middle East but data regarding treatment with pegylated interferon alpha and ribavirin of European populations infected with HCV-4 remains limited. Interestingly, European (vs. Egyptian) origin has been associated with lower sustained virological response rates. Hence the aim of this study was to investigate the treatment outcomes of Greek (vs. Egyptian), treatment-naïve patients infected with HCV-4 (subtype a) and to identify factors influencing response rates. One hundred seventy-seven consecutive patients (mean age: 44.6 ± 10.2, males: 143/177; 80.8%, Egyptians: 76/177; 42.9%) treated over a 7-year period at the Hepatology clinics of three tertiary care hospitals in Greece were retrospectively evaluated. Overall, sustained virological response was achieved in 75/177 (42.4%) of the cohort without a significant difference between the two ethnic groups [Greek: 44/101 (43.6%); Egyptian 31/76 (40.8%), P = 0.7598]. In multivariate analysis, it was found that ethnicity was not associated with an impaired response but age ≥45 years [odds ratio (OR): 0.4225, 95% confidence interval (CI): 0.2135-0.8133; P = 0.0134], diabetes (OR: 0.2346, 95% CI: 0.0816-0.0674; P = 0.0071), advanced liver fibrosis (OR: 0.3964, 95% CI: 0.1933-0.8133; P = 0.0116), and treatment suspension (OR: 0.1738, 95% CI: 0.0482-0.6262; P = 0.0075) showed an independent negative association with response to antiviral treatment. In contrast to previous European data suggesting Egyptian ethnicity to be a positive predictor for a sustained virological response, there was no influence of Greek versus Egyptian ethnicity on treatment outcomes. Higher age, advanced liver fibrosis, and diabetes have been shown to reduce significantly response rates in patients infected with HCV-4.


Subject(s)
Antiviral Agents/therapeutic use , Black People , Hepacivirus/genetics , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/ethnology , White People , Adult , Antiviral Agents/administration & dosage , Drug Therapy, Combination , Egypt , Female , Genotype , Greece , Hepacivirus/drug effects , Hepatitis C, Chronic/epidemiology , Hepatitis C, Chronic/virology , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Interferon-alpha/therapeutic use , Male , Middle Aged , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/therapeutic use , Predictive Value of Tests , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Ribavirin/administration & dosage , Ribavirin/therapeutic use , Treatment Outcome
4.
World J Gastroenterol ; 17(15): 1989-95, 2011 Apr 21.
Article in English | MEDLINE | ID: mdl-21528077

ABSTRACT

AIM: To investigate the technical success and clinical complication rate of a cannulated pancreatic duct with guidewire for biliary access. METHODS: During a five-year study period, a total of 2843 patients were included in this retrospective analysis. Initial biliary cannulation method consisted of single-guidewire technique (SGT) for up to 5 attempts, followed by double-guidewire technique (DGT) when repeated unintentional pancreatic duct cannulation had taken place. Pre-cut papillotomy technique was reserved for when DGT had failed or no pancreatic duct cannulation had been previously achieved. Main outcome measurements were defined as biliary cannulation success and post-endoscopic retrograde cholangiopancreatography (ERCP) complication rate. RESULTS: SGT (92.3% success rate) was characterized by statistically significant enhanced patient outcome compared to either the DGT (43.8%, P < 0.001), pre-cut failed DGT (73%, P < 0.001) or pre-cut as first step method (80.6%, P = 0.002). Pre-cut as first step method offered a statistically significantly more favorable outcome compared to the DGT (P < 0.001). The incidence of post-ERCP pancreatitis did not differ in a statistically significant manner between either method (SGT: 5.3%, DGT: 6.1%, Pre-cut failed DGT: 7.9%, Pre-cut as first step: 7.5%) or with patients' gender. CONCLUSION: Although DGT success rate proved not to be superior to SGT or pre-cut papillotomy, it is considered highly satisfactory in terms of safety in order to avoid the risk of a pre-cut when biliary therapy is necessary in difficult-to-cannulate cases.


Subject(s)
Bile Ducts/surgery , Catheterization/methods , Cholangiopancreatography, Endoscopic Retrograde/instrumentation , Cholangiopancreatography, Endoscopic Retrograde/methods , Pancreatic Ducts/surgery , Aged , Catheterization/adverse effects , Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Female , Humans , Male , Retrospective Studies , Sphincterotomy, Endoscopic/methods , Treatment Outcome
5.
Surg Endosc ; 25(3): 756-63, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20927548

ABSTRACT

BACKGROUND: Postoperative anastomotic strictures frequently complicate colorectal resection. Currently, various endoscopic techniques are being employed in their management, but the establishment of an optimal therapeutic strategy is still pending. The purpose of our study is to compare through-the-scope (TTS) balloon dilators versus Eder-Puestow metal olive dilators in the treatment of postoperative benign rectal strictures, considering the clinical outcome and cost-effectiveness of each method. METHODS: A total of 39 patients with benign anastomotic rectal stenosis were retrospectively studied. In group A, 15 patients underwent dilation with Eder-Puestow metal olives, while in group B 19 patients were treated by means of TTS balloon dilators. The technical and clinical success of dilation, complications, number of repeated sessions required, disease-free time intervals, and the overall cost of each procedure were evaluated. RESULTS: Dilations were technically successful in all patients. No major complications occurred in either group. The number of dilations needed, rate of stricture recurrence, and duration of stenosis-free time intervals were not statistically significantly different between the two groups. Both methods proved more effective in older patients, given the greater number of dilations required in younger patients of both groups and higher frequency of stricture relapse in younger balloon-dilated patients (median 64.00 years) compared with older ones (median 75.00 years) (p = 0.001). An indisputable advantage of the Eder-Puestow technique, compared with TTS balloon dilators, is the low cost of equipment (median 22.30 compared with 680 , respectively; p < 0.001). CONCLUSION: Endoscopic dilation of postoperative benign rectal strictures is equally effective and safe, especially in older patients, when performed by Eder-Puestow bougies or TTS balloon dilators. However, metal olivary tips seem to surpass balloon dilators when considering the obvious economical benefits of the first method.


Subject(s)
Catheterization/instrumentation , Cicatrix/surgery , Dilatation/instrumentation , Postoperative Complications/surgery , Rectum/surgery , Aged , Aged, 80 and over , Anastomosis, Surgical/adverse effects , Anastomosis, Surgical/methods , Catheterization/economics , Cicatrix/etiology , Colonoscopy/economics , Constriction, Pathologic/economics , Constriction, Pathologic/surgery , Cost-Benefit Analysis , Dilatation/economics , Direct Service Costs , Equipment Design , Female , Follow-Up Studies , Hospital Costs , Hospitalization/economics , Humans , Male , Middle Aged , Personnel, Hospital/economics , Recurrence , Retrospective Studies , Surgical Stapling/adverse effects
6.
Eur J Gastroenterol Hepatol ; 22(9): 1058-65, 2010 Sep.
Article in English | MEDLINE | ID: mdl-21061492

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate the satisfaction of patients with chronic hepatitis C who used the pegylated interferon α-2b pen device. METHODS: Patients from multiple centers in Greece were recruited to participate in this noninterventional, observational study. Patients received pen device training for at least 6 weeks before treatment and used questionnaires to provide feedback (rating scale: 1-4, negative; 5-7, positive) on training, medication preparation and injection, and appreciation of the device. Results were analyzed with standard statistical analysis and multivariate logistic regression. RESULTS: In total, 507 patients (mean age, 43.5 years), 77.4% of whom were treatment naive, participated in the study. Overall, 84.2% of patients rated training positively, 67.4% of patients rated medication preparation positively, and 88.3% of patients rated medication injection positively. Appreciation of the pen device treatment method was rated positively by 82.2% of patients. Intravenous drug users were more likely to rate medication injection positively (P=0.0284) and to appreciate this method of drug delivery (P=0.0328) than other patients. Patients with lower levels of education were less likely to rate training positively (P=0.0202) and showed less appreciation for this route of drug delivery (P=0.0341) than other patients. Treatment-naive patients were more likely to provide positive responses about the overall procedure than were treatment-experienced patients (odds ratio: 1.932; P=0.032). Adverse events were reported by 6.4% (29 of 453) of patients. CONCLUSION: Patients were satisfied with the pegylated interferon α-2b pen device; therefore, good treatment adherence is expected with its use.


Subject(s)
Antiviral Agents/administration & dosage , Hepatitis C, Chronic/drug therapy , Injections/instrumentation , Interferon-alpha/administration & dosage , Patient Satisfaction , Polyethylene Glycols/administration & dosage , Ribavirin/administration & dosage , Adult , Antiviral Agents/adverse effects , Drug Therapy, Combination , Equipment Design , Female , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Logistic Models , Male , Middle Aged , Patient Education as Topic , Polyethylene Glycols/adverse effects , Recombinant Proteins , Ribavirin/adverse effects , Surveys and Questionnaires
7.
Hepat Mon ; 10(3): 193-8, 2010.
Article in English | MEDLINE | ID: mdl-22308139

ABSTRACT

BACKGROUND AND AIMS: Despite the recent spread of hepatitis C virus genotype 4 (HCV-4) into European countries, very little is known about the influence of ethnicity on treatment outcomes in patients with HCV-4. The aim of this study was to compare the virologic response (VR) rates of: rapid virologic response (RVR), early virologic response (EVR), VR at 24 weeks of treatment, at end of treatment (EoT), and sustained virologic response (SVR) of European and Egyptian HCV-4 patients. METHODS: Sixty (30 Europeans - Group A; and 30 Egyptians - Group B) chronic HCV-4 subtype A adult patients with elevated baseline viral load (>800 000 IU/m L) were treated for a fixed period of 48 weeks with pegylated interferon α2a (PEG-IFN- α2a) and ribavirin. During the study, HCV-RNA levels were measured at weeks 4,12,24,48 and 72. RESULTS: Baseline characteristics, including liver histology, were similar in the two groups. RVR, EVR and HCV-RNA at week 24 in Groups A and B were (RVR 26.7% vs. 30.0%) (EVR 23.3% vs. 16.7%) (in week 24 13.3% vs. 16.7%). Overall SVR rates were 36.7% (11/30) for Group A and 26.7% (8/30) for Group B (P = 0.59). For group B, RVR was the weakest indicator for SVR as compared with RVR of group A, where RVR was the best SVR indicator CONCLUSIONS: The overall response to treatment was similar, but ethnic origin or previous history and treatment of schistosomiasis may influence intermediate response rates of chronic HCV-4a infected patients with elevated baseline HCV-RNA.

8.
Eur J Gastroenterol Hepatol ; 21(12): 1407-12, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19916203

ABSTRACT

INTRODUCTION: Chronic hepatitis C virus infection (HCV) is the most common infectious disease among intravenous drug users. AIMS: To determine and compare compliance rates between two groups of chronic HCV patients from the methadone substitution program of the National Greek Organization Against Drugs treated with either pegylated interferon alpha-2b/ribavirin or with interferon alpha-2b/ribavirin during 48 weeks of therapy and 24 weeks of follow-up. Furthermore, to evaluate the efficacy of each treatment modality. METHODS: Forty-five consecutive methadone maintenance (MM) patients (group A, 36 males, nine females) were treated with pegylated interferon alpha-2b (weight-based dosing 1.5 microg/kg/week) and ribavirin 1000-1200 mg/day orally. Sixty-five consecutive MM patients (group B, 52 males, 13 females) were treated with interferon alpha-2b (6 MIU, three times/week) and ribavirin with the doses reported above. During the study, all patients were followed up periodically by hepatologists, internists, and psychiatrists. RESULTS: Baseline characteristics were similar between the two groups. Thirty-four out of 45 patients (75.6%) from group A and 31 of 65 patients (47.7%) from group B completed therapy (P =0.006). Thirty-two (71.1%) patients from group A and 27 patients (41.5%) from group B were followed-up until the end of week 72 (P = 0.004). At the end of the follow-up, sustained virologic response was achieved in 23 of 45 (51.1%) patients from group A and 21 of 65 patients (32.3%) from group B (P =0.075). CONCLUSION: Pegylated interferon alpha-2b/ribavirin treatment achieved a significantly higher compliance rate than interferon alpha-2b/ribavirin in MM patients with chronic HCV infection. After 24 weeks of follow-up, response rates were similar for patients who were compliant to treatment for both groups.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Opiate Substitution Treatment , Patient Compliance , Adult , Antidepressive Agents/therapeutic use , Antiviral Agents/adverse effects , Drug Therapy, Combination , Drug Utilization/statistics & numerical data , Female , Follow-Up Studies , Hepatitis C, Chronic/complications , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Interferon-alpha/therapeutic use , Male , Methadone , Polyethylene Glycols/adverse effects , Polyethylene Glycols/therapeutic use , Recombinant Proteins , Ribavirin/adverse effects , Ribavirin/therapeutic use , Substance Abuse, Intravenous/complications , Substance Abuse, Intravenous/rehabilitation , Treatment Outcome
10.
Salud(i)ciencia (Impresa) ; 15(2): 531-534, abr. 2007.
Article in Spanish | LILACS, BINACIS | ID: biblio-1123433

ABSTRACT

The carcinoid tumor, argentaffinoma, is a member of a very exclusive neoplastic family known as neuroendocrine or amine precursor uptake and decarboxylation (APUD) tumors. Carcinoids have been found to arise from almost every organ and system derived from the primitive endoderm, but most frequently originated from the gastrointestinal tract, accounting for approximately half of all gastrointestinal endocrine tumors. Over 95% of all gastrointestinal carcinoids are located in only three sites: the appendix, rectum and small intestine. Irrespectively to their location, carcinoids are capable of producing various peptides. These tumors may present at different disease stages with either hormonal or hormonalrelated symptoms/syndromes, or without hormonal symptoms and may occur either sporadically or as a part of hereditary syndromes. Their clinical course is often indolent but can also be aggressive and resistant to treatment. This review provides a broad outline of progress that has been made in the elucidation of their clinical and laboratory diagnosis including recent advances in genetics, molecular biology, histopathology, biochemical markers, radiologic and scintigraphic imaging and endoscopy of gastrointestinal carcinoid tumors


Los tumores carcinoides, argentafinomas, son miembros de una familia particular de tumores conocida como familia de tumores neuroendocrinos o del sistema APUD (amine precursor uptake and decarboxilation: captación y descarboxilación de precursores de aminas). Los tumores carcinoides se originan en los órganos y sistemas derivados del endodermo primitivo, pero más frecuentemente en el tracto gastrointestinal, donde representan aproximadamente la mitad de todos los tumores endocrinos gastrointestinales. Más del 95% de todos los carcinoides gastrointestinales se localizan en tres sitios: el apéndice, el recto y el intestino delgado. Independientemente de su localización, los carcinoides pueden sintetizar varios péptidos. Estos tumores pueden presentarse en diferentes estadios patológicos con síntomas o síndromes hormonales o sin ellos, y pueden presentarse en forma esporádica o como parte de síndromes hereditarios. Su evolución clínica suele ser indolente pero también puede ser agresiva y resistente al tratamiento. Esta revisión describe el progreso realizado en el esclarecimiento de su diagnóstico clínico y de laboratorio e incluye avances recientes en genética, biología molecular, histopatología, marcadores bioquímicos, diagnóstico por imágenes radiológico y centellográfico y endoscopia de los tumores carcinoides gastrointestinales


Subject(s)
Humans , Somatostatin , Carcinoid Tumor , Neuroendocrine Tumors , Gastrointestinal Tract , Gastrointestinal Neoplasms
11.
Indian J Gastroenterol ; 26(5): 209-13, 2007.
Article in English | MEDLINE | ID: mdl-18227568

ABSTRACT

OBJECTIVE: To evaluate the effect of shortened duration of pegylated interferon (PEG-IFN) and ribavirin (RIB) treatment on sustained virological response (SVR) rates in treatment-naomicronve patients with chronic hepatitis due to genotype 2 or 3 hepatitis C virus (HCV) infection and high pre-treatment viral load (>800,000 IU/mL). METHODS: Records of 142 patients with chronic hepatitis C (22 with cirrhosis) who had been treated with PEG-IFN and RIB for 24 weeks (Group A, n=88), both drugs for 12-16 weeks (Group B, n=39), or with PEG-IFN for 12-16 weeks and RIB for 24 weeks (Group C, n=15), were analyzed retrospectively. RESULTS: Overall, 81.7% of patients had SVR (Group A: 88.6%, Group B: 69.2% and Group C: 73.3%, p=0.02). Failure to achieve SVR was significantly related to treatment group (p=0.026 for Group B and p=0.002 for Group C, versus Group A), older age (p=0.023), higher liver biopsy stage (p=0.001) and presence of cirrhosis (p< 0.0001). In patients without cirrhosis, only the treatment group (p=0.018 for Group B and p=0.002 for Group C, compared to Group A) independently predicted failure to achieve SVR. CONCLUSION: Shorter duration of PEG-IFN treatment (12-16 weeks) adversely affected the SVR rate in patients with genotype 2 or 3 HCV infection. However, increasing the duration of RIB administration (12-16 weeks versus 24 weeks) in such patients did not have any beneficial effect on SVR in patients receiving short-duration PEG-IFN.


Subject(s)
Antiviral Agents/administration & dosage , Hepacivirus/genetics , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/genetics , Interferon-alpha/administration & dosage , Ribavirin/administration & dosage , Adult , Aged , Drug Administration Schedule , Female , Genotype , Hepatitis C, Chronic/virology , Humans , Interferon alpha-2 , Male , Middle Aged , Polyethylene Glycols , Recombinant Proteins , Retrospective Studies , Time Factors , Treatment Outcome , Viral Load
12.
Clin Ther ; 27(6): 746-54, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16117981

ABSTRACT

BACKGROUND: Infrared photocoagulation (IRP) is commonly used in the treatment of hemorrhoids, but rectal bleeding can persist after this procedure. Adjuvant therapy may thus be considered for more definitive control of symptoms, particularly bleeding. OBJECTIVE: The goal of this study was to compare the efficacy of a treatment combining IRP and oral micronized purified flavonoid fraction (MPFF) versus each treatment used alone on bleeding cessation in patients with grades I, II, and III acute internal hemorrhoids. METHODS: This was a prospective, randomized, controlled, single-blind study. Consecutive outpatients were randomly assigned to a treatment combining MPFF and IRP or to each treatment separately. For each patient, bleeding status was reported at day 0 (day of inclusion) and compared with that at day 5 after treatment by observers blinded to treatment assignment. Follow-up visits were planned at days 7, 30, 60, and 90 of therapy, including monitoring of treatment-related side effects and self-reporting by patients of any problem related to hemorrhoidal disease. RESULTS: A total of 351 patients (180 women, 171 men) were enrolled in the study. Their mean age was 49.2 years (range, 29-71 years). Hemorrhoids were grade I in 33.6% (118 patients), grade II in 48.7% (171 patients), and grade III in 17.7% (62 patients) of the study population. Patients were randomly assigned to each of the 3 treatment groups (117 patients in each), with no significant difference between groups in the age, sex, or distribution of grade of hemorrhoids. The percentage of patients with no bleeding after 5 days of treatment was higher in the combined treatment group (74.8%) compared with MPFF alone (59.6%; P = 0.023) or with IRP alone (55.6%; P = 0.004). MPFF alone was as effective as IRP alone at stopping bleeding. Patients with grades I and II hemorrhoids responded significantly better (82.5% and 61.7%, respectively) to either treatment than those with grade III hemorrhoids (22.9%; P < 0.001). Of the 216 patients who were followed up for 90 days, 3 had a gastrointestinal adverse event, and 19 had a relapse of bleeding. CONCLUSION: Five days of treatment combining MPFF with IRP significantly reduced bleeding status in these study patients with grades I and II acute internal hemorrhoids compared with each treatment used alone.


Subject(s)
Flavonoids/therapeutic use , Hemorrhoids/therapy , Infrared Rays/therapeutic use , Light Coagulation/methods , Administration, Oral , Administration, Topical , Adult , Aged , Combined Modality Therapy , Dose-Response Relationship, Drug , Female , Flavonoids/administration & dosage , Gastrointestinal Hemorrhage/complications , Gastrointestinal Hemorrhage/prevention & control , Gastrointestinal Hemorrhage/therapy , Hemorrhoids/complications , Humans , Male , Middle Aged , Prospective Studies , Single-Blind Method , Tablets , Treatment Outcome
13.
World J Gastroenterol ; 11(42): 6644-9, 2005 Nov 14.
Article in English | MEDLINE | ID: mdl-16425358

ABSTRACT

AIM: To assess the frequency of herpes simplex virus type I in upper gastrointestinal tract ulcers and normal mucosa with the modern and better assays and also with a larger number of well characterized patients and controls and its relationship to Helicobacter pylori(H pylori). METHODS: Biopsy specimens from 90 patients (34 with gastric ulcer of the prepyloric area and 56 with duodenal ulcer) were evaluated. Biopsies from 50 patients with endoscopically healthy mucosa were considered as the control group. The method used to identify herpes simplex virus-1 (HSV-1) was polymerase chain reaction. H pylori was detected by the CLO-test and by histological method. RESULTS: Herpes simplex virus-1 was detected in 28 of 90 patients with peptic ulcer (31%) [11 of 34 patients with gastric ulcer (32.4%) and 17 of 56 with duodenal ulcer (30.4%)] exclusively close to the ulcerous lesion. All control group samples were negative for HSV-1. The likelihood of H pylori negativity among peptic ulcer patients was significantly higher in HSV-1 positive cases than in HSV-1 negative cases (P = 0.009). Gastric ulcer patients with HSV-1 positivity were strongly associated with an increased possibility of Helicobacter pylori negativity compared to duodenal ulcer patients (P = 0.010). CONCLUSION: HSV-1 is frequent in upper gastro-intestinal tract ulcers but not in normal gastric and duodenal mucosa. There is an inverse association between HSV-1 and H pylori infection.


Subject(s)
Helicobacter Infections , Helicobacter pylori/metabolism , Herpesvirus 1, Human/metabolism , Peptic Ulcer/virology , Adult , Aged , Aged, 80 and over , Biopsy , Female , Gastric Mucosa/anatomy & histology , Gastric Mucosa/microbiology , Gastric Mucosa/virology , Helicobacter Infections/microbiology , Helicobacter Infections/pathology , Herpesvirus 1, Human/genetics , Humans , Male , Middle Aged , Peptic Ulcer/microbiology , Peptic Ulcer/pathology , Polymerase Chain Reaction , Risk Factors , Statistics as Topic
14.
J Gastroenterol Hepatol ; 19(12): 1397-402, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15610314

ABSTRACT

BACKGROUND AND AIM: The aim of this study was to evaluate the efficacy and safety of endoscopic therapy with self-expanding metallic endoprostheses in the management of malignant esophageal obstruction or stenosis and the cost-effectiveness of the method in patients suffering from primary esophageal carcinoma. All patients with inoperable esophageal cancers treated with either laser palliation or endoprosthesis insertion were studied retrospectively. METHOD: Between May 1997 and December 2002 obstruction of the esophagus was diagnosed in 78 patients (52 male, 26 female, age range 53-102 years, mean 72.3 years). The etiology of obstruction was squamous cell carcinoma (n = 42) and adenocarcinoma of the esophagus (n = 36). The site of obstruction was in the upper (n = 1), in the middle (n = 38) and in the lower esophagus (n = 39). In 16 cases the gastroesophageal junction was also involved. Four patients had broncho-esophageal fistulas. In all cases the tumor was considered non-resectable. A total of 89 Ultraflex metal stents were introduced endoscopically. In 46 patients dilation with Savary dilators prior to stent placement was required. RESULTS: Stents were placed successfully in all patients. After 48 h, all patients were able to tolerate solid or semisolid food. During the follow-up period eight patients developed dysphagia due to food impaction (treated successfully endoscopically). Eleven patients presented with recurrent dysphagia 4-16 weeks after stenting due to tumor overgrowth and were treated with placement of a second stent. The median survival time was 18 weeks. There was no survival difference between squamous cell and esophageal adenocarcinoma. A cost-effective analysis was performed, comparing esophageal stenting with laser therapy. The mean survival and the cost were similar. A small difference of 156 Euro was noted (3.103 Euro and 2.947 Euro for each group of patients, respectively). A significant improvement in quality of life was noted in patients that underwent stenting (96% and 75%vs 71% and 57% for the first 2 months). CONCLUSION: Placement of self-expanding metal stents is a safe and cost effective treatment modality that improve the quality of life, as compared with other palliative techniques, for patients with inoperable malignant esophageal obstructions. In cases of expansion of the mass a second stent can be used; however, the overall survival of these patients, is poor.


Subject(s)
Esophageal Neoplasms/economics , Esophageal Neoplasms/surgery , Quality of Life , Stents/economics , Aged , Aged, 80 and over , Cost-Benefit Analysis , Equipment Design , Female , Humans , Laser Therapy , Male , Middle Aged , Retrospective Studies
15.
Hepatogastroenterology ; 49(47): 1245-50, 2002.
Article in English | MEDLINE | ID: mdl-12239914

ABSTRACT

BACKGROUND/AIMS: The overexpression of somatostatin receptors in the liver of some patients with hepatocellular carcinoma is well documented. The daily administration of octreotide in patients with advanced hepatocellular carcinoma was shown to have a marginal clinical effectiveness. The aim of the study was to estimate if and to what extent the administration of octreotide long-acting formulation (Sandostatin LAR) improves survival and quality of life in patients with advanced unresectable hepatocellular carcinoma. METHODOLOGY: Twenty-eight cirrhotic patients (stages A-B) with advanced hepatocellular carcinoma were enrolled in the study. Octreoscan scintigraphy for detection of STTR was performed in all cases. If it showed intense uptake in the liver, octreotide was administered as follows: Sandostatin 0.5 mg subcutaneous every 8 hours for 6 weeks. At the end of weeks 4-8 Sandostatin LAR 20 mg and at the end of week 12 and every 4 weeks Sandostatin LAR 30 mg intramuscularly. Patients' follow-up was worked out monthly. Thirteen patients unable to receive treatment were used as control group. RESULTS: Comparison of results between the 2 groups showed a significant difference in the median survival time (31 vs. 16 weeks, p = 0.037) and an improvement of quality of life (60% vs. 23.07%). Also, treated group showed a 72% reduction in the risk of dying during the follow-up period (p = 0.002). No alpha-fetoprotein reduction and decrease of the tumor mass was observed. CONCLUSIONS: In conclusion, the administration of Sandostatin LAR it appears to improve the survival and the quality of life in patients with advanced hepatocellular carcinoma.


Subject(s)
Antineoplastic Agents, Hormonal/administration & dosage , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Octreotide/administration & dosage , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/diagnostic imaging , Female , Humans , Liver Neoplasms/diagnostic imaging , Male , Middle Aged , Proportional Hazards Models , Quality of Life , Radionuclide Imaging , Receptors, Somatostatin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...